Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden
· Delayed Price · Currency is SEK 3.650
+0.005 (0.14%)
Mar 28, 2025, 5:29 PM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 46.1 | 57.6 | 22.6 | 38.2 | 40.66 | Upgrade
|
| Revenue | 46.1 | 57.6 | 22.6 | 38.2 | 40.66 | Upgrade
|
| Revenue Growth (YoY) | -19.96% | 154.87% | -40.84% | -6.05% | -50.75% | Upgrade
|
| Cost of Revenue | 11.6 | 204.5 | 142.6 | 96.6 | 185.17 | Upgrade
|
| Gross Profit | 34.5 | -146.9 | -120 | -58.4 | -144.51 | Upgrade
|
| Selling, General & Admin | 215.3 | 169.8 | 74.3 | 44.6 | 32.15 | Upgrade
|
| Research & Development | 146.2 | - | - | - | - | Upgrade
|
| Other Operating Expenses | 2.4 | - | - | -0.3 | - | Upgrade
|
| Operating Expenses | 363.9 | 173.4 | 77 | 46.8 | 32.55 | Upgrade
|
| Operating Income | -329.4 | -320.3 | -197 | -105.2 | -177.06 | Upgrade
|
| Interest Expense | -25.9 | -4.1 | -0.1 | -0.2 | -0 | Upgrade
|
| Interest & Investment Income | 16.5 | 4.9 | 0.9 | 0.1 | 0.16 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -4.6 | 2.4 | 0.6 | -1.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.5 | -2.7 | - | 0.2 | 0 | Upgrade
|
| Pretax Income | -343.3 | -326.8 | -193.8 | -104.5 | -178.02 | Upgrade
|
| Income Tax Expense | 0.3 | 0.1 | - | - | - | Upgrade
|
| Net Income | -343.6 | -326.9 | -193.8 | -104.5 | -178.02 | Upgrade
|
| Net Income to Common | -343.6 | -326.9 | -193.8 | -104.5 | -178.02 | Upgrade
|
| Shares Outstanding (Basic) | 307 | 257 | 194 | 180 | 67 | Upgrade
|
| Shares Outstanding (Diluted) | 311 | 260 | 194 | 180 | 67 | Upgrade
|
| Shares Change (YoY) | 19.57% | 33.86% | 7.97% | 166.96% | 30.54% | Upgrade
|
| EPS (Basic) | -1.12 | -1.27 | -1.00 | -0.58 | -2.64 | Upgrade
|
| EPS (Diluted) | -1.12 | -1.30 | -1.00 | -0.60 | -2.64 | Upgrade
|
| Free Cash Flow | -227.9 | -278.4 | -173.5 | -130.3 | -134.66 | Upgrade
|
| Free Cash Flow Per Share | -0.73 | -1.07 | -0.89 | -0.72 | -2.00 | Upgrade
|
| Gross Margin | 74.84% | -255.03% | - | -152.88% | - | Upgrade
|
| Operating Margin | -714.53% | -556.08% | -871.68% | -275.39% | -435.43% | Upgrade
|
| Profit Margin | -745.34% | -567.53% | -857.52% | -273.56% | -437.81% | Upgrade
|
| Free Cash Flow Margin | -494.36% | -483.33% | -767.70% | -341.10% | -331.18% | Upgrade
|
| EBITDA | -325.8 | -316.7 | -195.8 | -104 | -176.88 | Upgrade
|
| EBITDA Margin | - | - | - | -272.25% | - | Upgrade
|
| D&A For EBITDA | 3.6 | 3.6 | 1.2 | 1.2 | 0.18 | Upgrade
|
| EBIT | -329.4 | -320.3 | -197 | -105.2 | -177.06 | Upgrade
|
| EBIT Margin | - | - | - | -275.39% | - | Upgrade
|
| Revenue as Reported | - | 57.6 | 22.6 | 38.5 | 40.66 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.